Targeted Therapies for Prostate Cancer

REFERENCES

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–1403
   PubMed Web of Science ®Google Scholar
• Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol 2009;10:981–991.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. AFFIRM investigators increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012, Sep 27;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–223.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147–1154.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, Jul 29;363(5):411–422. doi:10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, the PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014 Jul 31;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman MR. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 2006;61:401–408.
   PubMedGoogle Scholar
• Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523–527.
   PubMed Web of Science ®Google Scholar
• Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res 2001;61:2533–2536.
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005;11:1815–1820.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol 2006;24:250–253.
   PubMed Web of Science ®Google Scholar
• Chiron M, Lejeune P, Pascale B, Bladt F, Vrignaud P, Bissery M-C. Broad spectrum of antitumor activity of afl ibercept (VEGF Trap) in tumor-bearing mice. American Association for Cancer Research Annual Meeting, San Diego, CA; April 12–16, 2008; abstract 380.
   Google Scholar
• Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1–2 study of docetaxel plus afl ibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12:1109–1117.
   PubMed Web of Science ®Google Scholar
• Isambert N, Freyer G, Zanetta S, You B, Fumoleau P, Falandry C, Favier L, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Trillet-Lenoir V. Phase I dose-escalation study of intravenous afl ibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2012;18:1743–1750.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M, VENICE Investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet Oncol 2013, Jul;14(8):760–768.
   PubMed Web of Science ®Google Scholar
• Paňares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7:433–445.
   PubMed Web of Science ®Google Scholar
• Picus J, Halabi S, Rini N, Vogelzang, Whang Y, Kaplan E, Kelly W, Small E. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22: abstr 1578.
   Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdonà S, Giordano A, Giuliano M, Labianca R, De Placido S. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A phase 2 study. Eur Urol 2008;54:1089–1094.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–1540.
   PubMed Web of Science ®Google Scholar
• Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532–2539.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Resto-Garces K, Tibyan M. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 2009;27(Suppl):272S (abstr 5156).
   Google Scholar
• Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16(4):417–425.
   PubMed Web of Science ®Google Scholar
• Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070–2076.
   PubMed Web of Science ®Google Scholar
• Fizazi, K. The role of Src in prostate cancer. Ann Oncol 2007;18(11):1765–1773.
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Elovani JG, Kim SJ, Wang Z, Gallick GE. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323–3333.
   PubMed Web of Science ®Google Scholar
• Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15: 3540–3549.
   PubMed Web of Science ®Google Scholar
• Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journé F. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010;10:298.
   PubMedGoogle Scholar
• Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263–268.
   PubMed Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421–7428.
   PubMed Web of Science ®Google Scholar
• Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1–2 study. Cancer 2012;118:63–71.
   PubMed Web of Science ®Google Scholar
• Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial. Lancet Oncol 2013, Dec;14(13):1307–1316.
   PubMed Web of Science ®Google Scholar
• You WK, McDonald DM. The hepatocyte growth factor/c-Met signalling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008;41:833–839.
   PubMed Web of Science ®Google Scholar
• Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study. J Clin Oncol 2014, Oct 20;32(30):3391–3399.
   PubMed Web of Science ®Google Scholar
• Scher HI, Smith MR, Sweeney C. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. J Clin Oncol 2013;31(Suppl): abstract 5026.
   Google Scholar
• Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009, May;20(5):913–920.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, Feb;21(2):319–324.
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014, Jan 10;32(2):76–82.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010, Nov;21(11):2135–2144.
   PubMed Web of Science ®Google Scholar
• Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nature Rev Urol 2010;7(9):494–509.
   PubMed Web of Science ®Google Scholar
• Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008;40:1443–1451.
   PubMed Web of Science ®Google Scholar
• Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169:1143–1149.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. A phase I–II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270–6276.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Tangen CM, Hussain M.SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol 2012;Suppl:30. [abstract 4511].
   PubMedGoogle Scholar
• James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebo-controlled, randomized phase II trial. BJU Int 2010;106:966–973.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov Registry. 2011. A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 10 mg ZD4054 (zibotentan) in combination with docetaxel in comparison with docetaxel in patients with metastatic hormone-resistant prostate cancer (ENTHUSE M1C) identifier NCT00617669. Available from: http://clinicaltrials.( [accessed 31 August 2011].
   Google Scholar
• ClinicalTrials.Gov Registry. 2011. A phase III, randomised, placebo-controlled, double-blind study to assess the efficacy and safety of once-daily orally administered ZD4054 (zibotentan) 10 mg in non-metastatic hormoneresistant prostate cancer patients (ENTHUSE M0) Identifier NCT00626548. Available from: http://clinicaltrials.gov/ct2/show/NCT00626548 [accessed 1 September 2011].
   Google Scholar
• ClinicalTrials.Gov Registry. 2011. A phase III trial to test the efficacy of ZD4054 (zibotentan), an endothelin a receptor antagonist, versus placebo in patients with hormone resistant prostate cancer (HRPC) and bone metastasis who are pain free and mildly symptomatic (ENTHUSE M1) identifier NCT00554229. Available from: http://clinicaltrials.gov/ct2/show/NCT00554229 [accessed 31 August 2011].
   Google Scholar
• Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013, May 10;31(14):1740–1747.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Iqbal F. CTLA-4 blockade: Therapeutic potential in cancer treatments. Onco Targets Ther 2010;3:15–25.
   PubMed Web of Science ®Google Scholar
• Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert OpinBiol Ther 2007;7(8):1245–1256.
   PubMed Web of Science ®Google Scholar
• O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13(3):958–964.
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985–7994.
   PubMed Web of Science ®Google Scholar
• Gerritsen W, Kwon ED, Fizazi K. CA184–043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs. placebo (pbo), each following single-dose radiotherapy (RT). In European Cancer Congress 2013, 27 September–1 October, Amsterdam, the Netherlands, 2013. Available at: http: //oncologypro.esmo.org/ (Abstract 2850).
   Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Isaacs JT. The long and winding road for the development of tasquinimod as an oral second generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Invest Drugs 2010;19(10):1235–1243.
   PubMed Web of Science ®Google Scholar
• Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022–4028.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332–342.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunol 2014, May 16;3(5):e16. doi:10.1038/cti.2014.7. eCollection 2014 May. Review.
   PubMedGoogle Scholar
• Junghans RP, Ma Q, Rathore R, Davies R, Bais A, Gomes E, et al. Abstract C13: phase I trial of anti-PSMA designer T cells in advanced prostate cancer. Cancer Res 2012;72(4 Supplement):C13.
   PubMedGoogle Scholar
• Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(27):4247–4254.
   PubMed Web of Science ®Google Scholar
• Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60:170–176.
   PubMed Web of Science ®Google Scholar
• Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel- refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102:389–397.
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247–4254.
   PubMed Web of Science ®Google Scholar
• Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011;17:5765–5773.
   PubMed Web of Science ®Google Scholar
• Heath EI, Stein MN, Vaishampayan UN. Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: Results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study. J Clin Oncol 2013;31(Suppl): abstract 5085.
   Google Scholar
• Chi K, Yu E, Ellard S. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with metastatic castration resistant prostate cancer. In ESMO Congress, Vienna, Austria, Sep 2012. Abstract 900PD.
   Google Scholar
• Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Therap 2007;6(1):101–111.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTCmulticenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009;20(7):1264–1269.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 2012, Jul;23(7):1803–1808.
   PubMed Web of Science ®Google Scholar
• Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study. BJC 2010;103(3):332–339.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010;116(4):1075–1083.
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgenindependent prostate cancer. J Clin Oncol 2004;22:2522–2531.
   PubMed Web of Science ®Google Scholar
• Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177 lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591–4601.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Milowsky MI, Morris M. Phase II trial of 177 lutetium radio-labeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). J Clin Oncol 2008;26(Suppl 15):284s; abstract 5140.
   Google Scholar
• Reid AHM, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5(11):610–620.
   PubMedGoogle Scholar
• Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69(10):4434–4442.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol 2010;6(5):665–679.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: Foundation for marker-driven treatment of prostate cancer. Cancer Discov 2013;3(8):849–861.
   PubMed Web of Science ®Google Scholar
• van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013;49(18):3821–3830.
   PubMed Web of Science ®Google Scholar
• Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 2014;(10):1135–1140.
   Google Scholar
• Buonerba C, Federico P, Bosso D, Puglia L, Policastro T, Izzo M, Perri F, Vittoria Scarpati GD, Ferro M, Cobelli OD, De Placido S, Aieta M, Imbimbo C, Longo N, Di Lorenzo G. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. Future Oncol 2014;10(8): 1353–1360.
   PubMed Web of Science ®Google Scholar
• Petrioli R, Roviello G, Fiaschi AI, Laera L, Miano ST, De Rubertis G, Barbanti G, Bianco V, Brozzetti S, Francini E. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: A single-institution experience. Med Oncol 2015,Mar;32(3):485.
   Google Scholar
• Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520–529.
   PubMed Web of Science ®Google Scholar